Table 2.
Primary serum | Clones | Source | Titer | Antigen retrieval |
---|---|---|---|---|
Bcl‐2 | 124 | Dako | 1 : 200 | EDTA/Tris, pH 9.0 |
Cleaved Caspase‐3 | Polyclonal | Cell Signaling | 1 : 1000 | Citrate buffer, pH 6.0 |
Survivin | Polyclonal | Neomarkers | 1 : 350 | Citrate buffer, pH 6.0 |
Par‐4 | A‐10 | Santa Cruz | 1 : 700 | Citrate buffer, pH 6.0 |
MUC1 | Ma552 | Novocastra | 1 : 500 | Citrate buffer, pH 6.0 |
PHLDA1 | M‐20 | Santa Cruz | 1 : 100 | Citrate buffer, pH 6.0 |
SPARC | Polyclonal | Chemicon | 1 : 6000 | Trilogy* |
Fas | EPR5700 | LSBio | 1 : 700 | Trilogy |
FasL | Polyclonal | LSBio | 1 : 700 | Trilogy |
Ki‐67 | 30‐9 | Roche | Ready to use | Automated protocol (Ventana, Roche) |
Fas, Fas cell surface death receptor; FasL, Fas ligand; Par‐4, prostate apoptosis response‐4; PHLDA1, pleckstrin homology‐like domain family A member 1; Bcl‐2, B‐cell CLL/lymphoma 2; MUC1, mucin 1; SPARC, secreted protein acidic and cysteine‐rich.
Trilogy, solution that allows deparaffinisation and antigen retrieval in a one‐step procedure.